secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aurinia Pharmaceuticals Inc. (AUPH)
CIK:        0001600620
Form:       8-K
Filed at:   2026-05-11T13:20:50+00:00
Accession:  0001140361-26-020402
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 2.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aurinia completes acquisition of Kezar Life Sciences for $6.955/share plus CVR
------------------------------------------------------------------------------

- Offer price: $6.955 cash per share plus one contingent value right (CVR).
- 5,927,580 shares tendered (~80.24% of outstanding) as of Expiration Time on May 8, 2026.
- Merger completed on May 11, 2026 under DGCL Section 251(h); no stockholder vote required.
- Outstanding in-the-money options converted to cash spread plus CVRs; out-of-the-money options cancelled.
- CVR Agreement dated May 11, 2026 with Broadridge as Rights Agent and Fortis Advisors as Representative.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1600620/000114036126020402/0001140361-26-020402-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1600620/000114036126020402/ef20072568_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-020402

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer